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Abstract
Objective To investigate the efficacy and tolerability of analgesic and
adjuvant pain drugs typically administered in primary care for the
management of patients with sciatica.
Design Systematic review.
Data source International Pharmaceutical Abstracts, PsycINFO, Medline,
Embase, Cochrane Central Register of Clinical Trials (CENTRAL),
CINAHL, and LILACS.
Study selection Randomised controlled trials assessing the efficacy
and tolerability of drugs versus placebo or other treatment for sciatica.
Data extraction Two independent reviewers extracted data and
assessed methodological quality using the PEDro scale. Pain and
disability outcomes were converted to a common 0 to 100 scale. Data
were pooled with a random effects model, and the GRADE approach
was used in summary conclusions.
Results Twenty three published reports met the inclusion criteria. The
evidence to judge the efficacy of non-steroidal anti-inflammatory drugs
(NSAIDs), corticosteroids, antidepressants, anticonvulsants, muscle
relaxants, and opioid analgesics ranged from moderate to low quality.
Most of the pooled estimates did not favour the active treatment over
placebo. The pooled results of two trials of corticosteroids (mean
difference in overall and leg pain −12.2, 95% confidence interval −20.9
to −3.4) and a single trial of the anticonvulsant gabapentin for chronic
sciatica (mean difference in overall pain relief −26.6, −38.3 to −14.9)
showed some benefits but only in the short term. The median rate of
adverse events was 17% (interquartile range 10-30%) for the active
drugs and 11% (3-23%) for placebo. Trial limitations included failure to
use validated outcome measures, lack of long term follow-up, and small
sample size.
Conclusions As the existing evidence from clinical trials is of low quality,
the efficacy and tolerability of drugs commonly prescribed for the
management of sciatica in primary care is unclear.
Introduction
The clinical syndrome of sciatica has been recognised since
ancient times. Currently believed to arise from a disorder of the
nerveroot,thesyndromeisknownbyarangeofsynonymssuch
as lumbosacral radicular syndrome, nerve root compromise,
nerve root pain, and nerve root entrapment or irritation.
1 2
Sciatica is considered to be a prognostic indicator of poor
outcomeamongpatientswithlowbackpain
3 4withasubstantial
proportion continuing to have persistent pain for two years or
longer.
5 The annual prevalence of sciatica is estimated to be
between 14%
6 and 2%.
7 While there are a range of definitions
of sciatica,
2 the key clinical features that can help clinicians to
distinguishitfromnon-specificlowbackpainincludeunilateral
leg pain that is worse than the low back pain, pain radiating
below the knee, presence of numbness or pins and needles in a
dermatomal distribution, positive results on a straight leg raise
test, and weakness or reflex changes, or both, in a myotomal
distribution.
1
Analgesic and adjuvant pain drugs are often prescribed for
patients with sciatica.
8 Patients with a clinical diagnosis of
sciaticaareaboutfivetimesmorelikelytotakedrugsthanthose
with low back pain only.
4 Drugs commonly prescribed for the
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Research
RESEARCHmanagementofsciaticaincludenon-steroidalanti-inflammatory
drugs (NSAIDs), skeletal muscle relaxants, opioid analgesics,
benzodiazepines,systemiccorticosteroids,antidepressants,and
anticonvulsants.
9 10Whileguidelinesprovideclearandgenerally
consistent recommendations for the prescription of drugs for
non-specific low back pain,
11 12 this is not the case for sciatica.
Atpresenttheefficacyandtolerabilityofcommonlyprescribed
analgesic and adjuvant drugs for the management of patients
withsciaticahasnotbeenestablished.Theproblemisthatthere
are no reviews that specifically focus on these drugs that are
used in primary care to manage sciatica. Because most
guidelines recommend a course of conservative care before
surgery is considered, it is imperative to understand what best
practice conservative care should entail. In this systematic
review we determined the efficacy and tolerability of analgesic
and adjuvant pain drugs typically administered in primary care
(orally, topically, or parentally) in the management of patients
with sciatica when compared with other treatment options or
no treatment.
Methods
Data sources and searches
We used the review methods advocated by the editorial board
of the Cochrane Back Review Group.
13 This study searched the
followingdatabasesfromtheearliestrecordsto15March2010:
International Pharmaceutical Abstracts, PsycINFO, Medline,
Embase,CochraneCentralRegisterofClinicalTrials,CINAHL,
andLILACS.Keywordsrelatedtorandomisedcontrolledtrial,
sciatica,anddrugstermsinadditiontosubjectsubheadingsand
word truncations specific for each database were used (see
appendixonbmj.com).Electronicsearchesweresupplemented
by hand searching reference lists of eligible clinical trials. Our
search was restricted to trials published in English, German,
Dutch, Portuguese, and Spanish. One reviewer screened all
relevant titles and abstracts and excluded clearly irrelevant
papers, leaving 173 potentially relevant papers. Two reviewers
independently evaluated the full reports for eligibility.
Disagreements were resolved by discussion.
Study selection
Studies were eligible if they were randomised controlled trials
evaluating single or any combination of analgesic or adjuvant
pain drugs. For the purposes of this review, we focused on
pharmacological interventions that could be administered in
primary care settings, which include drugs administered via
oral, topical, or parental route (that is, intramuscular injection
andintravenousbolus).Weexcludedtrialsevaluatingprocedures
thatrequireimagingassistanceandthemonitoringofanaesthesia
monitoring capabilities (for example, epidural, extradural, and
intradiscalinjections)orthatrequireanextendedperiodoftime
to be administered with monitoring of the patient’s vital signs
(for example, intravenous infusion). Eligible comparisons
included no treatment, placebo, or other treatment options (for
example, other pharmacological treatment, surgery, epidural
injections, or other conservative treatment).
Tobeeligiblestudiesneededtoexplicitlyreportthatparticipants
had sciatica or a synonym for sciatica. Sciatica synonyms
considered included radiculopathy, nerve root compromise,
nerverootcompression,lumbosacralradicularsyndrome,nerve
root pain, nerve root entrapment, and pain radiating below the
knee. The intensity or duration of symptoms was not restricted,
but participants were classified as having acute (less than six
weeks), subacute (six to 12 weeks), or chronic (12 weeks or
more) symptoms. Trials of mixed groups of patients with low
back pain were eligible if it was possible to clearly identify a
subgroup with sciatica and data only from these participants
were included in the analysis. There was no restriction related
to the source of participants. Sciatica definitions across trials
were classified as those based on clinical assessment alone and
those that also require concordant imaging evidence.
Trial drugs were classified according to the Anatomical
Therapeutic Chemical (ATC) classification system advocated
by the World Health Organization’s collaborating centre for
drugsstatisticsmethodology.
14Table1liststheclassesofdrugs
andtheATCcodesincludedinthesearchstrategyoftheoriginal
protocol⇓.
Trials were included when one of the following outcome
measures was reported: overall pain intensity (when not
specified as leg or back pain), leg or back pain intensity,
disability status, work status, and adverse events. We also
included studies that did not report continuous data for these
variables but reported percentage of improved patients. As the
definition of improved (or not improved) was unclear or varied
between studies, however, we did not pool these data. Work
status, when identified, was listed as an outcome but pooling
of these data was also not possible because of different
definitions used across trials.
Data extraction and quality assessment
Twotrainedindependentratersassessedthequalityofthetrials’
methodsusingthePEDroscale.
15 16Disagreementswereresolved
by a third rater. Methodological quality was not an inclusion
criterion.
Two independent reviewers extracted means (final scores or
change score), standard deviations, and sample sizes from
studies using a standardised data extraction form. When there
was insufficient information in trial reports, we contacted
authors or estimated data using methods recommended in the
CochraneHandbookforSystematicReviewsofInterventions.
17
Briefly, when the mean was not reported we used the median;
when standard deviations could not be estimated, we adopted
the standard deviation from the most similar study.
To evaluate the overall quality of the evidence and the strength
of the recommendation, we used the GRADE approach.
18 We
used an adapted version of the criteria advocated by the
Cochrane Back Review Group.
19 The quality of the evidence
was downgraded by one level for each of four factors we
encountered: limitations in the design (for instance, >25% of
participants from studies with low quality methods—PEDro
score <7 points); inconsistency of results (for instance, ≤75%
of the participants report findings in the same direction); and
imprecision (for instance, total number of participants <300 for
each outcome). We did not assess publication bias with funnel
plots as too few studies were included in the meta-analysis. We
also did not assess indirectness as this review encompasses a
specificpopulation.Tworeviewersjudgedwhetherthesefactors
werepresentforeachoutcome.Singlerandomisedstudies(with
under 300 participants) were considered inconsistent and
imprecise (that is, sparse data) and provided “low quality
evidence.” This could be further downgraded to “very low
quality evidence” if there were also limitations in design. We
applied the following definitions of quality of the evidence
20:
• High quality—further research is unlikely to change our
confidence in the estimate of effect. There are no known
or suspected reporting biases; all domains fulfilled
• Moderate quality—further research is likely to have an
importantimpactonourconfidenceintheestimateofeffect
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RESEARCHand might change the estimate; one of the domains was
not fulfilled
• Lowquality—furtherresearchislikelytohaveanimportant
impact on our confidence in the estimate of effect and is
likely to change the estimate; two of the domains were not
fulfilled
• Very low quality—we are uncertain about the estimate;
three of the domains were not fulfilled.
A GRADE profile was completed for each pooled estimate and
for single trials comparing drugs versus placebo.
Data synthesis and analysis
Outcome data were extracted for immediate term (two or fewer
weeks after randomisation), short term (more than two weeks
but less than three months), intermediate term (more than three
months but less than12 months), and long term (12 months or
more) follow-up evaluations. When multiple time points fell
within the same category, we used the one closest to one week
for the immediate term, eight weeks for the short term, six
months for the intermediate term, and 12 months for the long
term. Scores for pain intensity and disability were converted to
a scale from 0 to 100. When more than one outcome measure
was used to assess intensity of pain, disability, or work status,
we included the outcome measure described as the primary
outcome measure for the trial. Descriptive statistics were used
to describe adverse events reported in each trial.
Trialsthatweconsideredclinicallyhomogeneousweregrouped
according to class of drugs, comparison group, dose, outcomes
(pain, disability, etc), and outcome assessment time points
(immediateterm,shortterm,intermediateterm,andlongterm).
Pooled estimates were obtained with Comprehensive
Meta-Analysis software, version 2.2.04 (Biostat, Englewood,
NJ).Pooledeffectswerecalculatedwitharandomeffectsmodel.
For calculation of effect size (see appendix tables A and B on
bmj.com), we pooled leg pain and overall pain, as leg pain is
usually worse than pain in the back. When trials were not
sufficiently homogeneous, pooling of data via meta-analysis
was not performed and outcome measures of the individual
studies were reported. We decided a priori that a sensitivity
analysiswouldbeconductedtoinvestigatedefinitionsofsciatica
as possible sources of heterogeneity in effect size among
included studies. The limited number of trials in the
meta-analysis, however, prevented further investigation.
Results
Figure 1 outlines the flow of trials through the review⇓. The
initialelectronicdatabasesearchidentified2460potentialstudies
of interest. After screening citations by title and abstract, we
considered 197 potentially eligible articles for inclusion and
retrieved full articles. We included 23 published reports
21-43
(reporting 24 different clinical trials, as one
28 reported on two
trials). Three trials reported in previous systematic reviews
12 44-46
were not included in this review because of unclear
randomisation.
47-49
The included trials investigated six different classes of drugs:
NSAIDs, antidepressants, corticosteroids, opioid analgesics,
muscle relaxants, and anticonvulsants. The drugs investigated
in the included trials were administered orally in 16
trials
21-24 27 28 32 33 35-38 41-43 and parenterally in five trials (four
trials
25 30 39 40 investigated intramuscular injections and one trial
29
investigatedintravenousinfusions).Threeothertrials
26 31 34used
mixed administration of a starting intramuscular dose and
subsequent oral doses. One study compared oral versus
parenteral administration.
22 Table 2⇓ shows the characteristics
of the included trials, and table 3⇓presents details of
methodological quality.
Durationofsymptomsvariedalotacrossstudies(table2⇓).Six
trials specifically investigated patients with chronic
symptoms
21 23 37 38 41 43 and eight trials included patients with
acute symptoms.
22 28-30 33 35 42 In six trials, however, patients had
mixed duration of symptoms
25 27 34 36 39 40; in two trials duration
was not specified
26 32; and in two trials patients were reported
to have acute symptoms but no information regarding duration
was provided.
24 31 Regarding the definition of sciatica, 15 trials
used a definition based on clinical assessment
alone,
21 23 24 26 28 30-35 39 40 42 whereas nine trials also required
concordant imaging evidence.
22 25 27 29 36-38 41 43 Pooling of data
viameta-analysiswaspossibleonlyforcomparisonofNSAIDs
versus placebo in pain intensity at immediate follow-up and for
corticosteroids versus placebo in pain intensity at immediate
and short term follow-up. Table 2 also presents the number of
studies comparing each class of drug and control.⇓
Placebo controlled trials
Fifteen randomised clinical trials compared drugs with placebo
with individual effect sizes calculated for nine trials (fig 2⇓).
For five trials investigating NSAIDs,
31 corticosteroids,
32 34
antidepressants,
21 and muscle relaxants,
24 we did not calculate
effect sizes as percentage of improved patients was reported as
an outcome.
NSAIDs
FourtrialscomparedorallyadministeredNSAIDswithplacebo
for acute sciatica.
28 33 42 Of these, three trials used a three arm
design.
28 33 Treatment effects for these studies are presented in
figure2⇓.Dataforpoolingwereavailablefromallthreestudies.
Figure 3⇓ shows small and non-significant pooled effect size
for pain (overall and leg pain) in the immediate term follow-up
(mean difference −4.9, 95% confidence interval −10.2 to 0.4;
P<0.07). Because of the three arm design, we calculated effect
sizes for three other treatment comparisons (comparison 2
(meloxicam 7.5 mg/day, lornoxicam 8 mg/day, piroxicam 20
mg/dayvplacebo):meandifference−4.4,−8.9to0.1,I
2=0.1%,
P<0.06; comparison 3 (meloxicam 15 mg/day, lornoxicam 8
mg/day, piroxicam 2 mg/day v placebo): mean difference −3.9,
−8.0 to 0.2, I
2=0.6%, P<0.07; comparison 4 (meloxicam 15
mg/day, diclofenac 50-150 mg/day, piroxicam 20 mg/day v
placebo): mean difference −4.4, −9.4 to 0.6, I
2=6.8%, P<0.09)
(not shown in fig 3). The quality of evidence (GRADE) for this
pooling was rated “low quality” (downgraded for limitation of
study design and inconsistency).
Corticosteroids
Three trials in patients with acute sciatica tested the effect of
corticosteroids compared with placebo.
29 30 35 The individual
studies provided imprecise estimates of treatment effect (fig
2⇓). For the immediate term, pooling showed no effect of
steroidsonlegpain(meandifference−1.8,−11.1to7.5;P=0.71)
withaGRADEclassificationof“moderatequality”ofevidence
(downgraded for imprecision) (fig 3⇓). For the short term,
pooling showed a significant effect of steroids on pain (overall
and leg pain) (mean difference −12.2, −20.9 to −3.4; P<0.01)
and “moderate quality” of evidence according to the GRADE
approach (downgraded for imprecision) (fig 3⇓).
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RESEARCHAntidepressants, anticonvulsants, and opioid
analgesics
Three trials investigated the efficacy of antidepressants,
anticonvulsants, and opioid analgesics (fig 2⇓).
37 38 43 As these
were single trials that investigated different classes of drugs or
timepointsofassessment,poolingwasnotpossible.Hence,the
quality of evidence for all these medications was considered
“low quality” (single studies)
37 43 or “very low quality” (single
study downgraded for limitation of study design)
38 according
to the GRADE approach.
Two trials investigated the effect of anticonvulsants in patients
with chronic symptoms of sciatica. In one crossover trial,
38
topiramate(50-400mg/day)showednobetterimmediateeffects
thanplacebofordisabilityandlegorbackpain.Incontrast,data
from another trial
43 showed significant overall pain relieving
effect with the anticonvulsant gabapentin (900-3600 mg) in the
short term (mean difference −26.6, −38.3 to −14.9; P<0.001)
compared with placebo.
One crossover study with four periods investigated the relative
efficacy of opioid analgesics (sustained release morphine 15
mg/day), antidepressants (nortriptyline 25 mg/day), and a
combination of both and placebo in patients with chronic
sciatica.
37 In this trial, antidepressants, opioid analgesics, and a
combination of both had no significant effect compared with
placebointheimmediatetermfordisabilityorlegorbackpain.
NSAIDs v NSAIDs
Five studies compared one type of NSAID with other
NSAIDs.
25 28 33 39 40 Figure 4⇓ shows all the comparisons
involving different types of NSAIDs. None of these studies
showedoneNSAIDtobebetterthantheother.Onestudyfound
no difference in overall pain between oral and parenteral
administration of meloxicam 15 mg a day.
22
NSAIDs v other treatments
In three separate trials the NSAID diclofenac (50-75 mg/day)
showed no difference in outcomes compared with
antidepressant
36 or electroacupuncture
41 but did worse than
caudal epidural injections of corticosteroids
27 for pain and
disability, specifically in the immediate follow-up (fig 3⇓). In
one trial the NSAID ketoprofen (200 mg/day) was no better
than a combination of corticosteroids for pain in the immediate
follow-up.
26
Adverse events
Adverseeventswereinvestigatedin75%(18/24)oftheincluded
trials (table 4⇓); the median number of adverse events
(interquartile range) was 17% (10-30%) for the active drugs
and 11% (3-23%) for placebo. The rate and type of adverse
eventsreportedvariedsubstantiallybetweendrugsandbetween
trials for the same medicine.
Discussion
There is at best only low quality evidence to judge the efficacy
and tolerability of drugs commonly prescribed for the
managementofsciaticainprimarycare.Theavailableevidence
does not clearly show favourable effects of NSAIDs,
corticosteroids, antidepressants, or opioid analgesics in the
immediate term, even compared with placebo. Evidence from
a single trial and one meta-analysis with two trials provides
some limited support (“low quality” and “moderate quality”
evidence) for the use of NSAIDs and corticosteroids to relieve
pain in the short term in patients with acute sciatica. In one
small sample trial there was also limited support (“low quality”
evidence) for the short term relief of pain in chronic sciatica
with an anticonvulsant drug. At present these data provide a
lack of conclusive and high quality evidence to guide the
prescription of these drugs for patients with sciatica in primary
care.
Strengths and limitations of review
The strengths of this systematic review include the use of a
prespecifiedprotocol,inclusionoftrialspublishedinlanguages
other than English, and the use of a highly sensitive search
strategy to identify trials for sciatica coupled with search terms
related to the nine classes of drugs of interest. We assessed
methodological quality with the PEDro scale rather than the
Cochrane Risk of Bias tool because the PEDro scale has been
shown to have acceptable reliability
16 and validity,
15 50 whereas
two studies have reported reliability limitations with the
Cochrane tool.
51 52 One limitation of our study is the possibility
ofpublicationbiasaswedidnotattempttoidentifyunpublished
trials that could be found in clinical trials registries and
conference proceedings. Another limitation is that we could
accommodate trials in only four languages other than English.
A strength of our review over past reviews is that we located
24 randomised clinical trials relevant to our question compared
withsix,
12three,
46andtwo
44 45trialsincludedinthefourprevious
reviews. Accordingly we provide more precise estimates of
treatment effects, specifically for NSAIDs and corticosteroids,
and a better description about tolerability of all classes of drug.
Including more trialshas allowed us toprovide amore in-depth
evaluation of the pharmacological treatments that have been
tested for sciatica in primary care. For example, we have
provided information on the efficacy of antidepressants and
opioid analgesics whereas previous reviews did not cover these
classes of drugs. Another strength of this review is that we
quantitatively pooled trials where possible. This allowed us to
explore the size of the treatment effect, which is not possible in
a qualitative summary. In addition, we were able to assess the
overall quality of the evidence with the GRADE approach.
Although conclusions of previous reviews were based on a
surprisingpaucityofevidence,ourfindingsarelikelytoinform
thedirectionoffutureresearchinthistopic.Inpharmacological
trials for sciatica, we consider the priorities to include
consideration of duration of symptoms, recruitment of large
samples, and collection of outcomes relevant to patients. For
instance,regardingdurationofsymptomsitwouldbereasonable
to test corticosteroids and NSAIDs in trials in patients with
acute sciatica, whereas given that chronic sciatica includes a
neuropathicpaincomponent,anticonvulsantandantidepressants
might need to be tested in patients with a chronic condition.
Althoughtheknowledgeofevidenceaboutsurgeryhaschanged
in the past decade, we still do not know much about a simpler
conservative treatment such as pharmacological interventions
for sciatica. A recent clinical practice guideline from the
American Pain Society
53 recommends that surgery should be
considered as a treatment option for persistent and disabling
radicular pain caused by a herniated lumbar disc. This
recommendation relies on moderate short term benefits from
large randomised clinical trials such as those by Peul et al
54 55
and Weinstein et al,
56 with 283 and 501 patients randomised,
respectively. At present, there is a limited number of mainly
smalltrialsofpharmacologicalinterventionswithtypicallyshort
term follow-up. For example, the evidence to support the use
of anticonvulsants in chronic sciatica arises from a single trial
with only 50 participants.
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RESEARCHOur principal finding is that there is insufficient evidence to
confidently guide the use of any analgesic or adjuvant pain
medicine for the effective management of pain and disability
in patients with sciatica. Until this changes, we would advise
clinicians treating such patients who exhibit clinical features of
neuropathic pain to consider evidence based guidelines for
neuropathic pain
57-59 and for other patients with sciatica to
consider therapeutic recommendations from current guidelines
for the management of non-specific low back pain.
11
Contributors: RZP, CGM, BK, PHF, MLF, MH, and AJM were involved
in the design of the review. RZP, MLF, PHF, and VCO developed the
search strategy and performed the study selection. RZP, MH, AJM, and
VCO extracted data from included studies. RZP, CGM, BK, AJM, and
VCO were involved in data analysis. RZP, CGM, BK, PHF, MLF, and
MH were involved in the interpretation and discussion of results. All
authors contributed to the writing and review of the various drafts of the
report. RZP and CGM are guarantors.
Funding: This research received no specific grant from any funding
agency in the public, commercial, or not-for-profit sectors. RZP is
supported by Capes Foundation, Ministry of Education of Brazil. CGM
is supported by a research fellowship funded by the Australian Research
Council.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: no support from
any organisation for the submitted work; no financial relationships with
any organisations that might have an interest in the submitted work in
the previous three years; no other relationships or activities that could
appear to have influenced the submitted work.
Ethical approval: Nor required.
Data sharing: No additional data available.
1 Koes BW, van Tulder MW, Peul WC. Diagnosis and treatment of sciatica. BMJ
2007;334:1313-7.
2 Konstantinou K, Dunn KM. Sciatica: review of epidemiological studies and prevalence
estimates. Spine 2008;33:2464-72.
3 Balague F, Nordin M, Sheikhzadeh A, Echegoyen AC, Brisby H, Hoogewoud HM, et al.
Recovery of severe sciatica. Spine 1999;24:2516-24.
4 Selim AJ, Ren XS, Fincke G, Deyo RA, Rogers W, Miller D, et al. The importance of
radiating leg pain in assessing health outcomes among patients with low back pain.
Results from the Veterans’ Health Study. Spine 1998;23:470-4.
5 Tubach F, Beaute J, Leclerc A. Natural history and prognostic indicators of sciatica. J
Clin Epidemiol 2004;57:174-9.
6 Palmer KT, Griffin MJ, Syddall HE, Pannett B, Cooper C, Coggon D. The relative
importance of whole body vibration and occupational lifting as risk factors for low-back
pain. Occup Environ Med 2003;60:715-21.
7 Younes M, Bejia I, Aguir Z, Letaief M, Hassen-Zrour S, Touzi M, et al. Prevalence and
risk factors of disk-related sciatica in an urban population in Tunisia. Joint Bone Spine
2006;73:538-42.
8 Vogt MT, Kwoh CK, Cope DK, Osial TA, Culyba M, Starz TW. Analgesic usage for low
back pain: impact on health care costs and service use. Spine 2005;30:1075-81.
9 Cherkin DC, Wheeler KJ, Barlow W, Deyo RA. Medication use for low back pain in primary
care. Spine 1998;23:607-14.
10 Di Iorio D, Henley E, Doughty A. A survey of primary care physician practice patterns and
adherence to acute low back problem guidelines. Arch Fam Med 2000;9:1015-21.
11 Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview
of clinical guidelines for the management of non-specific low back pain in primary care.
Eur Spine J 2010;19:2075-94.
12 Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the
evidence for an American Pain Society/American College of Physicians clinical practice
guideline. Ann Intern Med 2007;147:505-14.
13 Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for
systematic reviews in the Cochrane Back Review Group. Spine 2009;34:1929-41.
14 WHO Collaborating Centre for Drugs Statistics Methodology. International language for
drug utilisation research. 2011. www.whocc.no/.
15 Macedo LG, Elkins MR, Maher CG, Moseley AM, Herbert RD, Sherrington C. There was
evidence of convergent and construct validity of Physiotherapy Evidence Database quality
scale for physiotherapy trials. J Clin Epidemiol 2010;63:920-5.
16 Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro
scale for rating quality of randomized controlled trials. Phys Ther 2003;83:713-21.
17 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version
5.0.2. Cochrane Collaboration, 2009.
18 Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of
evidence and strength of recommendations. BMJ 2004;328:1490.
19 Henschke N, Ostelo RW, van Tulder MW, Vlaeyen JW, Morley S, Assendelft WJ, et al.
Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev
2010;7:CD002014.
20 Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE:
an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ 2008;336:924-6.
21 Atkinson J, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, et al. A
placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain
1998;76:287-96.
22 Auvinet B, Ziller R, Appelboom T, Velicitat P. Comparison of the onset and intensity of
action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin
Ther 1995;17:1078-98.
23 Baron R, Freynhagen R, Tolle TR, Cloutier C, Leon T, Murphy TK, et al. The efficacy and
safety of pregabalin in the treatment of neuropathic pain associated with chronic
lumbosacral radiculopathy. Pain 2010;150:420-7.
24 Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to
evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res
1988;16:75-82.
25 Borms T. Comparison of injectable formulations of tiaprofenic acid and ketoprofen in acute
lumbar sciatica. Single-blind randomised trial. Drugs 1988;35:85-7.
26 Braun H, Huberty R. [Therapy of lumbar sciatica. A comparative clinical study of a
corticoid-free monosubstance and a corticoid-containing combination drug.] Med Welt
1982;33:490-1.
27 Dincer U, Kiralp MZ, Cakar E, Yasar E, Dursan H. Caudal epidural injection versus
non-steroidal anti-inflammatory drugs in the treatment of low back pain accompanied with
radicular pain. Joint Bone Spine 2007;74:467-71.
28 Dreiser RL, Le Parc JM, Velicitat P, Lleu PL. Oral meloxicam is effective in acute sciatica:
two randomised, double-blind trials versus placebo or diclofenac. Inflamm Res
2001;50:S17-23.
29 Finckh A, Zufferey P, Schurch MA, Balague F, Waldburger M, So AK. Short-term efficacy
of intravenous pulse glucocorticoids in acute discogenic sciatica. A randomized controlled
trial. Spine 2006;31:377-81.
30 Friedman BW, Esses D, Solorzano C, Choi HK, Cole M, Davitt M, et al. A randomized
placebo-controlled trial of single-dose IM corticosteroid for radicular low back pain. Spine
2008;33:e624-9.
31 Grevsten S, Johansson H. Phenylbutazone in treatment of acute lumbago-sciatica. Z
Rheumatol 1975;34:444-7.
32 Haimovic IC, Beresford HR. Dexamethasone is not superior to placebo for treating
lumbosacral radicular pain. Neurology 1986;36:1593-4.
33 Herrmann WA, Geertsen MS. Efficacy and safety of lornoxicam compared with placebo
and diclofenac in acute sciatica/lumbo-sciatica: an analysis from a randomised,
double-blind, multicentre, parallel-group study. Int J Clin Pract 2009;63:1613-21.
34 Hofferberth B, Gottschaldt M, Grass H, Buttner K. [The usefulness of
dexamethasonephosphate in the conservative treatment of lumbar pain—a double-blind
study (author’s translation).] Arch Psychiatr Nervenkr 1982;231:359-67.
35 Holve RL, Barkan H. Oral steroids in initial treatment of acute sciatica. J Am Board Fam
Med 2008;21:469-74.
36 Kanayama M, Hashimoto T, Shigenobu K, Oha F, Yamane S. New treatment of lumbar
disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled
trial. J Neurosurg Spine 2005;2:441-6.
37 Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs
placebo in patients with chronic lumbar root pain. Pain 2007;130:66-75.
38 Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. Topiramate in chronic
lumbar radicular pain. J Pain 2005;6:829-36.
39 Rachid A. Avaliação da eficácia e tolerância do cetoprofeno (200 mg/dia) comparada ao
diclofenac sódico (150 mg/dia) no tratamento da lombociatalgia aguda. [Evaluation of
efficacy and safety of ketoprofen (200 mg/day) compared to diclofenac (150 mg/day) in
the treatment of acute lombociatalgia.] Rev Bras Med 1992;49:37-40.
40 Schuermans Y, Rauis A. Comparative clinical trial of two injectable NSAIDs, tiaprofenic
acid and alclofenac, in acute sciatica. Drugs 1988;35(suppl 1):83-5.
41 Wang BX, La JL. Therapeutic effects of electro-acupuncture and diclofenic on herniation
of lumbar intervertebral disc. Zhongguo Linchuang Kangfu 2004;8:3413-5.
42 Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms
in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine
1993;18:1433-8.
43 Yildirim K, Sisecioglu M, Karatay S, Erdal A, Levent A, Ugur M, et al. The effectiveness
of gabapentin in patients with chronic radiculopathy. Pain Clinic 2003;15:213-8.
44 Luijsterburg PA, Verhagen AP, Ostelo RW, van Os TA, Peul WC, Koes BW. Effectiveness
of conservative treatments for the lumbosacral radicular syndrome: a systematic review.
Eur Spine J 2007;16:881-99.
45 Roelofs PDDM, Deyo RA, Koes BW, Scholten RJPM, van Tulder MW. Non-steroidal
anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2010;1:CD000396.
46 Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica:
a systematic review. J Spinal Disord 2000;13:463-9.
47 Goldie I. A clinical trial with indomethacin (indomee(R)) in low back pain and sciatica.
Acta Orthop Scand 1968;39:117-28.
48 Radin EL, Bryan RS. Phenylbutazone for prolapsed discs? Lancet 1968;2:736.
49 Weber H, Aasand G. The effect of phenylbutazone on patients with acute lumbago-sciatica.
A double blind trial. J Oslo City Hosp 1980;30:69-72.
50 De Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical
trials: a demographic study. Aust J Physiother 2009;55:129-33.
51 Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study
quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias
Tool and the Effective Public Health Practice Project Quality Assessment Tool:
methodological research. J Eval Clin Pract 2012;18:1218.
52 Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Krebs Seida J, et al. Risk of bias
versus quality assessment of randomised controlled trials: cross sectional study. BMJ
2009;339:b4012.
53 Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, et al. Interventional
therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based
clinical practice guideline from the American Pain Society. Spine 2009;34:1066-77.
54 Peul WC, van den Hout WB, Brand R, Thomeer RT, Koes BW. Prolonged conservative
care versus early surgery in patients with sciatica caused by lumbar disc herniation: two
year results of a randomised controlled trial. BMJ 2008;336:1355-8.
55 Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, et al.
Surgery versus prolonged conservative treatment for sciatica. N Engl J Med
2007;356:2245-56.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e497 doi: 10.1136/bmj.e497 (Published 13 February 2012) Page 5 of 15
RESEARCHWhat is already known on this topic
Pain relieving drugs are often prescribed by general practitioners for patients with sciatica
While guidelines provide clear and generally consistent recommendations for the prescription of drugs for non-specific low back pain,
this is not the case for sciatica
The efficacy and tolerability of drugs in the management of sciatica administered in primary care has not been established
What this study adds
There is low quality evidence for the efficacy of NSAIDs, corticosteroids, and anticonvulsants
The available evidence does not clearly show favourable effects of NSAIDs, corticosteroids, antidepressants, muscle relaxants, and
opioid analgesics in the immediate term and provides limited support for the use of NSAIDs, corticosteroids, and anticonvulsants in the
short term
At present these data provide a lack of conclusive and high quality evidence to endorse the prescription of these drugs for patients with
sciatica in primary care
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RESEARCHTables
Table 1| Classes of drugs and Anatomical Therapeutic Chemical (ATC) codes included in search strategy
ATC code
Analgesics:
N02 Any
N02A Opioid analgesics
N02BE01 Paracetamol
N03 Anticonvulsants (or antiepileptics)
N06A Antidepressants
N05BA Benzodiazepine derivatives
H02 Corticosteroids for systemic use
M01A Non-steroidal anti-inflammatory drugs
M03 Skeletal muscle relaxants
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RESEARCHTable 2| Characteristics of included studies of pain relief in patients with sciatica
Outcomes(measures)andtime
points Interventions (dose regimens and dosing duration) Details of participants Study
NSAID v placebo
% of improved patients; adverse
events; at two weeks
Group 1: IM phenylbutazone (0.6 g) on day 1, oral dose 0.2
g (two tablets) on days 2-4, oral dose 0.1 g (one tablet) in
days 5-15 v group 2: IM distilled water, NaOH 1N to pH8 (0.6
g) on day 1, oral dose 0.2 g (two tablets) on days 2-4, oral
dose 0.1 g (one tablet) on days 5-15. Additional analgesics
allowed
Source: outpatient department of surgical or
surgical-orthopaedic clinic; n=36; group 1=18,
group 2=18; age: 23-62; duration: acute (NS)
Grevsten 1975
31
Leg and back pain (0-100 scale);
disability (RM); adverse events;
work status
(no/sometimes/often); at 1, 2, 3,
and 4 weeks
Group 1: 20 mg oral piroxicam v group 2: oral placebo. Twice
daily for first two days, followed by once daily for next 12 days.
Additional analgesics allowed
Source: patients recruited from practitioners
and company doctors; n=208; group 1=120,
group 2=94; age=48 (SD NS); duration: acute
(onset of pain within 14 days)
Weber 1993
42
Dreisser 2001
28:
Overall pain (0-100 scale);
adverse events; day 3 and day
7
Group 1: 7.5 mg oral meloxicam v group 2: 15 mg oral
meloxicam v group 3: oral placebo. Once daily for 7 days
Source: 79 centres in 6 countries; n=532; group
1=117 (mean (SD) age 47 (14)), group 2=181
(47 (15)), group 3=180 (47 (14)); duration:
acute (onset of pain within 3 days)
Placebo control
study
Group 1: 7.5 mg oral meloxicam once daily v group 2: 15 mg
oral meloxicam once daily v group 3: 50 mg oral diclofenac
three times daily for 14 days. Additional analgesics allowed
in both studies
Source: 117 centres in 10 countries; n=489;
group 1=164 (mean (SD) age 46 (14)), group
2=163 (45 (14)), group 3=162 (44 (13));
duration: acute (onset of pain within 3 days)
Diclofenac
control study
Overall pain (0-100 scale),
adverse events, at 3, 4, 6, and 8
hours
Group 1: 8 mg oral lornoxicam×2 on day 1 (loading dose)+1
capsule after 8 hours, twice daily on day 2-4, once on day 5;
v group 2: 50 mg oral diclofenac one/day on day 1, 3 times/day
on days 2-4, once on day 5 (optional) v group 3: oral placebo
(capsules added to group 1 and group 2 blister packs)
Source: outpatients from general practices;
n=171; group 1=57 (mean (SD) age 52 (15)),
group 2= 57 (49 (14)), group 3=57 (48 (12));
duration: acute (onset of pain within 3 days)
Herrmann 2009
33
Corticosteroids v placebo
% of improved patients at 11
days, 6 weeks, and 6 months
Group 1: IM dexamethasone (168 mg) v group 2: IM placebo;
2 ampoules 3 times/day on day 1-5, one ampoule 3 times/day
on days 6-8, one ampoule twice on day 9, one ampoule on
day 10. Additional analgesics and physiotherapy were allowed
Source: NS; n=91; group 1=38, group 2=53;
age: 47 (range 30-70); duration: mixed ( >1
month)
Hofferberth 1982
34
% of improved patients at 7 days
and 12 months
Group 1: oral dexamethasone v group 2: oral placebo; 64 mg
on day 1, 32 mg on day 2, 16 mg on day 3, 12 mg on day 4,
8 mg on days 5-7. Additional analgesics allowed and
participants kept on bed rest for 7 days of treatment
Source: NS; n=33; group 1=21, group 2=12;
age: NS; duration: NS
Haimovic 1986
32
Leg pain (0-100 scale), adverse
events, on days 1-3 and day 10
Group 1: single IV infusion bolus of 500 mg
methylprednisolone v group 2: single intravenous infusion of
0.9% saline; additional analgesics, NSAIDs, glucocorticoids,
and physical therapy allowed
Source: university and non-university hospitals;
n=60; group 1=31 (mean (SD) age 49 (18)),
group 2=29 (45 (13)); duration: acute (>1week
to <6 weeks)
Finckh 2006
29
Pain (0-5 scale), disability (ODI),
adverse events, work status (No
of hours patients was employed),
at 1, 2, 3, and 4 weeks, and 2, 3,
4, 5, and 6 months
Group 1: oral prednisolone (60 mg/day for three days, 40
mg/day for 3 days, and 20 mg/day for 3 days) v group 2: oral
placebo (containing inert filler substance); daily oral
administration 60 mg on days 1-3, 40 mg on days 4-9, 20 mg
on days 7-9. Additional analgesics allowed and, if needed;
activity as tolerated; and referral to physical therapy
Source: primary care or emergency
departments; n=29; group 1=15 (age 39 (95%
CI 33 to 46), group 2=14 (43 (38 to 46));
duration: acute (onset of pain within 1 week)
Holve 2008
35
Overall pain (0-10 scale),
adverse events. Work status (rate
of return to work), at 1 month
Group 1: IM methylprednisolone (160 mg) v group 2: IM
placebo. Additional analgesics, opioid analgesics, and NSAIDs
allowed
Source: teaching hospital; n=82; group 1=39
(mean (SD) age 39 (9)), group 2=43 (37 (8);
duration: acute (≤7 days)
Friedman 2008
30
Antidepressant v placebo
% of improved patients at 8
weeks
Group 1: oral nortriptyline v group 2: oral doses of placebo.
Both groups received identical capsules: 25 mg/day for 3 days;
50 mg/day for 4 days, 75 mg for 3 days, and 100 mg/day for
4 days. Additional analgesics allowed
Source: university medical primary care centre,
orthopaedic clinic, and local community; n=15;
group 1=6 (mean (SD) age 46 (11)), group 2=9
(47 (11)); duration: chronic (≥6 months)
Atkinson 1998
21
Anticonvulsant v placebo
Overall pain (0-3 scale), adverse
events, at 1 and 2 months
Group 1: oral gabapentin 900-3600 mg divided in 3 doses on
day 1 depending on tolerability v group 2: oral placebo 3/day
for 8 weeks
Source: outpatient setting; n=50; group 1=25
(mean (SD) age 38 (7)), group 2=25 (41 (11));
duration: chronic (group 1= 69.3 (3-180)
months, group 2= 67.7 (5-240) months)
Yildirim 2003
43
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RESEARCHTable 2 (continued)
Outcomes(measures)andtime
points Interventions (dose regimens and dosing duration) Details of participants Study
Leg pain (0-10 scale), adverse
events at 8 weeks
Group 1: oral topiramate 50 mg in 2 divided doses in week 1,
50 mg increments in each morning and night doses to
Source: recruited through local newspaper
advertisements; n=29; age: 53 (28-74);
duration: chronic (>3 months)
Khoromi 2005
38
(cross over)
maximum of 400 mg in weeks 2-4 v group 2: oral doses of
diphenhydramine (placebo) 6.25 mg twice/day in week 1,
increased by 6.25 mg increments in each dose in week 2,
increased by 12.5 mg increments in each dose in week 3 to
maximum of 50 mg/day in 2 divided doses. Each period
consisted of 4 weeks of drug titration and 2 weeks of
maintenance, followed by 2 week washout, during which doses
were tapered
% of improved patients, adverse
events on day 7, 14, 21, 28, and
35
Group 1: oral pregabalin, 5 weeks at optimal dose established
in single blind phase) v group 2: oral placebo (pregabalin dose
tapered off during first 7 days, then placebo administered for
4 weeks). Trial started after 1 week single blind run-in phase
to identify and exclude placebo responders, followed by 4
week single blind pregabalin treatment phase with flexible
Source: 46 centres in 8 countries; n=217; group
1=110 (mean (SD) age 53 (11)), group 2=107
(53 (13)); duration: chronic (>3 months)
Baron 2010
23
dose pregabalin 150-600 mg/day to identify responders.
Additional analgesics allowed
Muscle relaxants v placebo
% of improved patients on day 3
and 7
Group 1: 4 mg oral tizanidine 3 times/day for 7 days v group
2: oral placebo (3 times/day for 7 days). Additional analgesics
allowed
Source: outpatients from general practices;
n=117; group 1=28 (mean (SD) age 44 (13)),
group 2=31(38 (13)); duration: acute (NS)
Berry and
Hutchinson, 1988
24
NSAID v NSAID*
Overall pain (0-100 scale),
adverse events on days 1, 2, 3,
and 4
Group 1: twice daily 200 mg IM tiaprofenic twice/day for 4
days v group 2: 100 mg IM ketoprofen twice/day for 4 days
Source: NS; n=40; group 1=20 (mean (SD) age
37 (10)), group =20 (42 (15)); duration: mixed
(<6 months)
Borms 1988
25
Overall pain (0-100 scale),
adverse events on days 1, 2, 3,
and 4
Group 1: 200 mg IM tiaprofenic twice/day for 4 days v group
2: 656 mg IM alclofenac twice/day for 4 days
Source: NS; n=26; group 1=14 (mean (SD) 50
(9)), group 2=12 (49 (13)); duration: mixed (<6
months)
Scheurmans
1988
40
Overall pain (0-100 scale),
adverse events on days 1, 2, 3,
4, 5, 6, and 7
Group 1: 100 mg/day IM intramuscular injections of ketoprofen
twice/day for 7 days v group 2: 75 mg/day IM diclofenac
twice/day for 7 days
Source: NS; n= 60; group 1=30 (mean (range)
age 51 (29-68)), group 2=30 (53 (26-60));
duration: mixed (<12 weeks)
Rachid 1992
39
Overall pain (0-100 scale),
adverse events at 15, 30, 45, 60,
75, and 90 min and 2, 3, 4, 6, 9,
24 hours
Group 1: IM meloxicam (15 mg in 1.5 ml aqueous solution)
and oral placebo (1 capsule) v group 2: 15 mg oral meloxicam
capsule and one 1.5 ml IM placebo injection. Patients kept on
strict bed rest during 24 hour study
Source: 22 centres in three countries; n=113;
group 1=54 (mean (SD) age 47 (10)), group
2=59 (42 (11)); duration: acute (<35 days)
Auvinet 1995
22
NSAID v corticosteroids combination
Overall pain (0-100 scale) on day
4 and 9
Group 1: 2×200 mg/day IM ketoprofen on days 1-3, (200
mg/day), 4×50 mg oral+1×100 mg suppository ketoprofen on
days 4-8 v group 2: 1st-3rd day 1 IM combination
(phenylbutazone, carbamoyl-phenoxyacetic acid,
dexamethasone, lidocaine (lignocaine) hydrochloride,
cyanocobalamin) on days 1-3, 3 oral capsules+1 suppository
on days 4-8. Additional analgesics allowed
Source: NS; n= 37; group 1=17, group 2=20);
age: NS; duration: NS
Braun 1982
26
NSAID v caudal epidural injection
Overall pain (0-10 scale),
disability (ODI) on day 15 and at
1 and 3 months
Group 1: 75 mg oral diclofenac twice/day for 14 days v group
2: single injection (40 mg methylprednisolone acetate, 8 mg
dexamethasone phosphate, 7 ml 2% prolocaine HCl, 10 ml
0.9% NaCl). Both groups instructed to perform lumbopelvic
mobilisation and lumbar stabilisation exercise on daily basis.
Additional analgesics allowed after day 14
Source: NS; n= 64; group 1=30 (mean (SD)
age 29 (6)), group 2=34 (28 (6)); duration:
mixed (>1 month to <12 months)
Dincer 2007
27
NSAID v acupuncture
Leg pain (0-10 scale) on day 7 Group 1: 25 mg oral diclofenac twice/day for 5 days v group
2: 25 minute electroacupuncture/day for 7 days
Source: outpatients from acupuncture centre;
n=40; group 1=23, group 2=17; age: NS;
duration: chronic (>2 years)
Wang 2004
41
NSAID v antidepressant
Leg and back pain (0-100 scale)
at 2 weeks
Group 1:75 mg oral diclofenac v group 2: 300 mg oral 5-HT
inhibitor for 2 weeks
Source: hospital (orthopaedic department);
n=40; group 1=20 (mean (SD) age 34 (17)),
group 2=20 32 (9)); duration: mixed (<1 to >3
months)
Kanayama 2005
36
Opioid analgesic v antidepressant v placebo
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RESEARCHTable 2 (continued)
Outcomes(measures)andtime
points Interventions (dose regimens and dosing duration) Details of participants Study
Leg and back pain (0-10),
disability (ODI), adverse events,
day 10
Group 1: 15 mg oral sustained release morphine v group 2:
25 mg oral nortriptyline v group 3: 15 mg oral morphine+25
mg nortriptyline v group 4: oral inert placebo (0.25 mg
Source: recruited through local newspaper
advertisements; n=28; age: 53 (range 19-65);
duration: chronic (≥3 months)
Khoromi 2007
37
(crossover study)
benztropine, mimics side effects of other). All drugs tapered
over 10 day period and patients drug-free for another 4 days
before starting next period. Doses above are starting doses,
subsequent doses depended on tolerability
IM=intramuscular; NS=not specified; IV=intravenous. ODI=Oswestry disability index. NSAID=non-steroidal anti-inflammatory drug. RM=Roland Morris disability
questionnaire.
*Dreiser
28 and Herman
33 could be included in this comparison as both studies included comparisons of NSAID v NSAID.
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RESEARCHTable 3| PEDro scores of included studies of pain relief in patients with sciatica
Total
(0-10)
Point
estimateand
Between
group Intention
to treat
analysis
< 15%
dropouts
Assessor
blinding
Therapist
blinding
Participant
blinding
Groups
similar at
baseline
Concealed
allocation
Random
allocation Study
variability
reported
difference
reported
6 Yes Yes No Yes Yes No Yes No No Yes Grevsten 1975
31
5 No No No Yes Yes No Yes Yes No Yes Weber 1993
42
8 Yes Yes Yes Yes Yes No Yes Yes No Yes Dreisser 2001
28*
9 No Yes Yes Yes Yes Yes Yes Yes Yes Yes Herrmann 2009
33
8 No Yes Yes Yes Yes Yes Yes No Yes Yes Hofferberth 1982
34
5 Yes No No Yes Yes No Yes No No Yes Haimovic 1986
32
8 No Yes No Yes Yes Yes Yes Yes Yes Yes Finckh 2006
29
7 Yes Yes No No Yes Yes Yes Yes No Yes Holve 2008
35
9 Yes Yes No Yes Yes Yes Yes Yes Yes Yes Friedman 2008
30
9 Yes Yes Yes No Yes Yes Yes Yes Yes Yes Atkinson 1998
21
7 Yes Yes No Yes Yes No Yes Yes No Yes Yildirim 2003
43
6 Yes Yes No No Yes Yes Yes No No Yes Khoromi 2005
38
8 Yes Yes Yes No Yes Yes Yes No Yes Yes Baron 2010
23
7 Yes Yes No Yes Yes No Yes Yes No Yes Berry 1988
24
4 Yes Yes No Yes No No No No No Yes Borms 1988
25
5 Yes Yes No Yes No No No Yes No Yes Scheurmans 1988
40
3 No Yes No No No No No Yes No Yes Rachid 1992
39
8 Yes Yes Yes Yes Yes No Yes Yes No Yes Auvinet 1995
22
6 No Yes Yes Yes Yes No Yes No No Yes Braun 1982
26
5 Yes Yes No Yes No No No Yes No Yes Dincer 2007
27
5 Yes Yes No Yes No No No Yes No Yes Wang 2004
41
5 Yes Yes No Yes No No No No Yes Yes Kanayama 2005
36
7 Yes Yes Yes No Yes Yes Yes No No Yes Khoromi 2007
37
*Dreisser et al
28 reported on two clinical trials.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e497 doi: 10.1136/bmj.e497 (Published 13 February 2012) Page 11 of 15
RESEARCHTable 4| Numbers of adverse events in numbers of cases and description for each study group
Description of adverse events Group 4 Group 3 Group 2 Group 1 Study
Mild transient nausea (6); gastritis (1) NS NS Placebo (4/18; 22%) Phenylbutazone 0.1-0.6 (3/18;
16%)
Grevsten 1975
31
Not explicitly stated NS NS Placebo (13/94; 14%) Piroxicam 20 mg (22/120;
18%)
Weber 1993
42
Abdominal pain (7); diarrhoea (3); dizziness (3);
dyspepsia (7); hepatic enzymes increased (2);
nausea (8)
NS Placebo (8/180;
4%)
Meloxicam 15 mg
(13/181; 7%)
Meloxicam 7.5 mg (9/117;
8%)
Dreisser 2001
28 (trial
1)
Abdominal pain (10); diarrhoea (10); dizziness (5);
dyspepsia (21); flatulence (6); headache (9); nausea
(11)
NS Diclofenac
(24/162; 15%)
Meloxicam 15 mg
(27/163; 17%)
Meloxicam 7.5 mg (21/164;
13%)
Dreisser 2001
28 (trial
2)
Dyspepsia (5); diarrhoea (5); nausea (4); abdominal
pain (3); flatulence (1); bronchitis (1), coughing (1),
sputum (w2), hyperuricaemia (2), bilirubinaemia
(1), myalgia (1), leg cramps (1)
NS Placebo (4/57;
7%)
Diclofenac 50 mg (7/57;
12%)
Lornoxicam 8 mg (6/57; 11%) Herrmann 2009
33
Epigastric complaints NS NS Placebo (4/53; 8%) Dexamethasone 168 mg
(13/38; 34%)
Hofferberth 1982
34
Transient hyperglycaemia (2); facial flush (1) NS NS Placebo (0) Methylprednisolone 500 mg
(3/31; 10%)
Finckh 2006
29
— NS NS Placebo (0) Prednisolone 20-60 mg (0) Holve 2008
35
Drowsiness (11); stomach pain (6); mood changes
(1); bloating (1)
NS NS Placebo (8/43; 19%) Methylprednisolone 160 mg
(11/39; 28%)
Friedman 2008
30
Dizziness (1); somnolence (1); chest pain (1);
fainting (1)
NS NS Placebo (0) Gabapentin 900-3600 mg
(2/25; 8%)
Yildirim 2003
43
Paraesthesia (17); fatigue/weakness (19); sedation
(11); diarrhoea (11); headache (6); constipation (2);
depression (2); joint pain (3); leg cramps (7);
amnesia (1); anorexia (1); frequent urination (1);
thirst (1); eyes twitching (1); oedema (1); speech
difficulty (1); blurred vision (1); photophobia (1);
NS NS Placebo (20/28; 72%) Topiramate 50-400 mg
(24/28; 86%)
Khoromi 2005
38*†
bleedings gums (1) ; tremor (1); somnolence (1);
extremely yellow urine (1); decreased libido (1)
Dizziness (6); somnolence (2); fatigue (2); dry
mouth (2); constipation (1); headache (5); weight
increase (5); peripheral oedema (7).
NS NS Placebo (26/107; 24%) Pregabalin 150-600 mg
(31/110; 28%)
Baron 2010
23‡
Stomach pain (7); allergic skin reaction (3); pain on
injection (3); dizziness (1); headache (1)
NS NS Ketoprofen 200 mg (9/20;
45%)
Tiaprofenic 400 mg (6/20;
30%)
Borms 1988
25
Pruritus (1); pain on injection (1); allergic skin
reaction (2); gastralgia (2); vertigo (1)
NS NS Alclofenac 1312 mg (4/12,
33%)
Tiaprofenic 400 mg (2/14;
14%)
Scheurmans 1988
40
Epigastric pain (9); nausea (11), pyrosis (6). NS NS Diclofenac 150 mg (10/30;
33%)
Ketoprofen 200 mg (11/30;
37%)
Rachid 1992
39
Erythematous rash (1); dizziness (1); headache (3);
dry mouth (2); palpitations (1); neutropenia (1);
leucopenia (1); nocturia (1)
NS NS Oral meloxicam 15mg
(6/59; 10%)
IM meloxicam 15 mg (5/52;
9%)
Auvinet 1995
22
— NS NS Combination preparation
(0)
Ketoprofen 200 mg (0) Braun 1982
26
Constipation (47); dry mouth (30); headache (14);
drowsiness (13); tired/fatigue (19); dizziness (8);
insomnia (8); nausea (3); difficulty urinating (4);
sexual dysfunction (4); abdominal pain (4);
weakness (2); decreased appetite (3); heartburn
(4); blurred vision (6); thirsty/dehydrated (2); weight
gain (2)
Placebo
(14/28; 50%)
Combination
(25/28; 89%)
Morphine 15 mg (26/28;
93%)
Nortriptyline 25 mg (19/28;
68%)
Khoromi 2007
37*
NA=not stated; IM=intramuscular.
*Crossover study and adverse effects only for completers.
†Nine patients dropped out from study because of adverse effects of topiramate: acral paraesthesia (2); nausea and anorexia (2); sedation and amnesia (3);
depression and anxiety (1); rash (1).
‡Only most common adverse events listed.
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RESEARCHFigures
Fig 1 Selection process of trials examining pain relief in patients with sciatica
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e497 doi: 10.1136/bmj.e497 (Published 13 February 2012) Page 13 of 15
RESEARCHFig 2 Mean difference for pain and disability in placebo controlled trials on pain relief in patients with sciatica. Overall pain,
leg pain, back pain, and disability expressed on common 0-100 scale. Immediate=follow-up evaluations ≤ 2 weeks after
randomisation; short term=follow-up evaluations >2 weeks but ≤3 months; intermediate=follow-up evaluations >3 months
but <12 months; long term=≥12 months. NSAID=non-steroidal anti-inflammatory drug
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RESEARCHFig 3 Pooled mean difference for immediate pain in trials comparing NSAID v placebo. Pain expressed on common 0-100
scale. Immediate=follow-up evaluations ≤2 weeks after randomisation; short term=follow-up evaluations >2 weeks but ≤3
months; intermediate=follow-up evaluations >3 months but <12 months; long term=≥12 months. NSAID=non-steroidal
anti-inflammatory drug
Fig 4 Mean difference for pain and disability in trials comparing NSAID versus NSAID or other treatments. Overall pain,
leg pain, back pain and disability expressed on common 0-100 scale. Immediate=follow-up evaluations ≤2 weeks after
randomisation; short term=follow-up evaluations >2 weeks but ≤3 months; intermediate=follow-up evaluations >3 months
but <12 months; long term=≥12 months. NSAID=non-steroidal anti-inflammatory drug. *Injection contains methylprednisolone
40 mg, dexamethasone 8 mg, 2% prolocaine 7 ml, 0.9% NaCL 10 ml)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e497 doi: 10.1136/bmj.e497 (Published 13 February 2012) Page 15 of 15
RESEARCH